Tong Ren Tang Technologies Co. Ltd. (TGRNF) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Tong Ren Tang Technologies Co. Ltd. (TGRNF) trades at $0.4949 with AI Score 48/100 (Grade C). Tong Ren Tang Technologies Co. Ltd. Market cap: $634M, Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Jun 14, 2026Analyst Coverage for TGRNF: TGRNF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates TGRNF against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
TGRNF: the 3 scored disciplines are evenly split. Dominant signal: Seth Klarman bullish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Tong Ren Tang Technologies Co. Ltd. (TGRNF) Healthcare & Pipeline Overview
Tong Ren Tang Technologies Co. Ltd. is a leading manufacturer of traditional Chinese medicine products, leveraging over 350 years of heritage to offer a diverse portfolio that includes pharmaceuticals, healthcare services, and raw materials, primarily serving the Mainland China and Hong Kong markets.
What Is the Investment Thesis for TGRNF?
Tong Ren Tang Technologies Co. Ltd. presents a compelling investment thesis driven by its strong market position in the traditional Chinese medicine sector, characterized by a P/E ratio of 10.1 and a profit margin of 6.1%. The company's historical growth trajectory and commitment to innovation in TCM products and services position it well for future expansion, particularly in the rapidly growing healthcare market in Asia. With a gross margin of 38.0%, Tong Ren Tang demonstrates operational efficiency, which could be enhanced through increased market penetration and product diversification. The ongoing demand for natural and holistic health solutions further supports the company's growth potential. Key value drivers include its established brand reputation, extensive product range, and strategic focus on research and development. However, investors should remain aware of potential risks, including regulatory challenges and market competition, particularly from domestic and international players.
Based on FMP financials and quantitative analysis
TGRNF Key Highlights
Market Cap of $634M reflects a solid presence in the healthcare sector.
- P/E ratio of 10.1 indicates a potentially undervalued stock compared to industry peers.
- Profit margin of 6.1% showcases the company's ability to maintain profitability amidst market competition.
- Gross margin of 38.0% exceeds many industry averages, indicating strong operational efficiency.
- Dividend yield of 5.49% provides a steady income stream for investors.
Who Are TGRNF's Competitors?
TGRNF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| TSUSF Tsuruha Holdings Inc. | $17.25 | +0.00% | $4.20B | 49 |
| JCRRF JCR Pharmaceuticals Co., Ltd. | $3.32 | +0.00% | $405M | 48 |
| LYPHF Luye Pharma Group Ltd. | $0.27 | +0.00% | $1.08B | 49 |
| PTKFF PT Kalbe Farma Tbk. | $0.04 | +0.00% | $1.82B | 47 |
| CELG-RI Bristol-Myers Squibb Company Ce | $0.10 | +2.31% | $208M | 57 |
| HAWPF Haw Par Corporation Limited | $12.58 | +0.00% | $2.78B | 49 |
| HAWPY Haw Par Corporation Limited | $53.50 | +0.00% | $2.96B | 50 |
| VRBCF Virbac S.A. | $383.25 | +0.00% | $3.21B | 54 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are TGRNF's Key Strengths?
Rich heritage and established brand recognition in TCM.
- Diverse product offerings that cater to a wide range of health needs.
- Strong operational efficiency reflected in gross and profit margins.
- Extensive distribution network across key markets.
What Are TGRNF's Weaknesses?
Dependence on the Chinese market for the majority of revenue.
- Limited international presence compared to global competitors.
- Potential regulatory challenges in expanding product lines.
- Vulnerability to shifts in consumer preferences towards Western medicine.
What Could Drive TGRNF Stock Higher?
Expansion into international markets to diversify revenue streams.
- Continuous product innovation in traditional Chinese medicine.
- Strategic partnerships with healthcare institutions to enhance credibility.
- Increased focus on digital marketing and e-commerce strategies.
- Commitment to sustainability initiatives to attract environmentally conscious consumers.
What Are the Key Risks for TGRNF?
Regulatory challenges affecting the traditional medicine sector.
- Intense competition from both local and international players.
- Market fluctuations impacting raw material costs.
- Changing consumer preferences towards alternative health solutions.
What Are the Growth Opportunities for TGRNF?
- Expansion into International Markets: Tong Ren Tang Technologies Co. Ltd. is poised for growth by expanding its product offerings into international markets, particularly in North America and Europe, where demand for traditional and natural health products is increasing. The global herbal medicine market is projected to reach $1.5 trillion by 2027, presenting a significant opportunity for the company to tap into new customer segments and diversify its revenue streams.
- Innovative Product Development: The company is focusing on developing new and innovative TCM products that cater to modern health needs. With the global dietary supplements market expected to grow at a CAGR of 8.5% from 2021 to 2028, Tong Ren Tang's commitment to R&D and product innovation positions it to capture a share of this expanding market, enhancing its competitive edge.
- Strategic Partnerships: Collaborating with healthcare institutions and research organizations could enhance Tong Ren Tang's credibility and facilitate the development of new therapies. Such partnerships can lead to advancements in clinical practices and the introduction of evidence-based TCM products, potentially increasing market penetration and consumer trust.
- Digital Transformation: Investing in e-commerce and digital marketing strategies can significantly boost Tong Ren Tang's sales channels. With the rise of online shopping, especially post-pandemic, the company can leverage digital platforms to reach a broader audience, particularly younger consumers who are increasingly interested in health and wellness products.
- Sustainability Initiatives: Emphasizing sustainable sourcing and production practices can enhance Tong Ren Tang's brand image and appeal to environmentally conscious consumers. As the global market shifts towards sustainability, the company can differentiate itself by promoting its commitment to eco-friendly practices, potentially attracting a new customer base.
What Are TGRNF's Competitive Advantages?
- Established brand reputation built over 350 years.
- Strong distribution network across Mainland China and Hong Kong.
- Diverse product portfolio catering to various health needs.
- Expertise in traditional Chinese medicine and healthcare services.
- Commitment to research and development for innovative product offerings.
What Does TGRNF Do?
Tong Ren Tang Technologies Co. Ltd., founded in 1669, is a distinguished company based in Beijing, People's Republic of China, with a rich history rooted in traditional Chinese medicine (TCM). The company has evolved significantly over the centuries, establishing itself as a key player in the healthcare sector. Its core operations focus on the manufacturing and marketing of TCM products, which are deeply integrated into the cultural fabric of China. Beyond finished goods, Tong Ren Tang also engages in the cultivation, procurement, and sale of Chinese medicinal raw materials, ensuring a steady supply chain for its products. The company's extensive product portfolio includes both conventional and traditional Chinese pharmaceuticals, biological products, cosmetics, and various healthcare and wellness items. Specialized products such as ointments, tea beverages, and foot care solutions further diversify its offerings. Tong Ren Tang distributes its products through both wholesale and retail channels, reaching a broad customer base. Additionally, the company provides a comprehensive suite of services, including medical research and development, advertising, and specialized Chinese medical consultation and treatment. Its healthcare services encompass internal and external surgical procedures, medical examinations, and hospital management. The company is also involved in advanced processing activities, such as plant extraction and the production of biochemical products, which positions it well within the growing market for natural and holistic health solutions.
What Products and Services Does TGRNF Offer?
- Manufacture and market traditional Chinese medicine products.
- Cultivate and procure Chinese medicinal raw materials.
- Produce a wide range of healthcare and wellness items, including pharmaceuticals and cosmetics.
- Provide medical research and development services.
- Offer specialized Chinese medical consultation and treatment.
- Engage in advanced processing activities, such as plant extraction.
How Does TGRNF Make Money?
- Revenue generated from the sale of traditional Chinese medicine products.
- Income from the cultivation and sale of medicinal raw materials.
- Fees from healthcare services, including surgeries and medical examinations.
- Sales of cosmetics and wellness products through wholesale and retail channels.
- Revenue from advertising and medical consultation services.
What Industry Does TGRNF Operate In?
The drug manufacturing industry, particularly in the realm of traditional Chinese medicine, is experiencing significant growth, driven by increasing consumer awareness of natural health products and a rising demand for holistic healthcare solutions. The global market for traditional medicine is projected to expand, with Asia-Pacific leading in consumption due to cultural preferences and government support for TCM. In this competitive landscape, Tong Ren Tang Technologies Co. Ltd. stands out due to its long-standing heritage and established brand, enabling it to leverage market trends effectively while facing competition from both local and international players such as Tsuruha Holdings Inc. (TSUSF).
Who Are TGRNF's Key Customers?
- Consumers seeking traditional Chinese medicine and wellness products.
- Healthcare institutions requiring medicinal raw materials.
- Patients seeking specialized medical consultations and treatments.
- Retailers and wholesalers distributing TCM products.
- Individuals interested in holistic health solutions.
Tong Ren Tang Technologies Co. Ltd. (TGRNF) Valuation Context
Valued at $634M, TGRNF is classified as a small-cap stock. Relative to its peer group, TGRNF's quantitative score of 48/100 is roughly in line with the peer average of 50/100.
TGRNF Revenue & Earnings Trend
In Q4 2025, TGRNF generated $2.70B in top-line revenue, marking a sequential decrease of 27.8%. The company recorded net income of $56.7M, with diluted EPS of $0.04. Quarter-over-quarter revenue has been mixed, typical for a small-cap company operating in Healthcare. Across the four most recent quarters, TGRNF averaged $0.18 in diluted EPS.
Company Profile
Tong Ren Tang Technologies Co. Ltd. operates in the Medical - Pharmaceuticals industry within the Healthcare sector. It is headquartered in Beijing, CN. The company is led by CEO Chun You Zhang. TGRNF has traded publicly since 2012.
Key Financial Metrics
Return on equity for Tong Ren Tang Technologies Co. Ltd. stands at 5.4%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 2.9%, showing how much profit it generates from its asset base. TGRNF trades at a trailing price-to-earnings ratio of 10.05, below the Healthcare sector average of ~23x. Its free cash flow yield is 40.1%, a gauge of the cash the business throws off relative to its market value. A current ratio of 5.72 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 10.8%, the inverse of the P/E and a quick read on earnings relative to price.
Financial Health
Tong Ren Tang Technologies Co. Ltd.'s Piotroski F-Score is 5/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 3.39 places it in the safe zone, indicating low near-term bankruptcy risk.
Forward Outlook
Wall Street analysts project Tong Ren Tang Technologies Co. Ltd. revenue of about $7.21B for fiscal 2026, with EPS near $0.37.
TGRNF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future prospects, indicating a belief in potential growth.
- Community sentiment has been increasingly positive, with many investors discussing the company's innovative product pipeline and expansion plans.
- The market has reacted favorably to Tong Ren Tang's recent partnerships, enhancing its brand visibility and market reach.
- Strong demand for traditional Chinese medicine has positioned the company well in a growing market, attracting attention from health-conscious consumers.
Bear Case
- Concerns about regulatory changes in the traditional medicine sector have raised doubts among some investors regarding future profitability.
- Community discussions reflect skepticism about the company's ability to scale operations effectively amid increasing competition.
- Recent earnings reports have shown mixed results, leading to uncertainty about the sustainability of its growth trajectory.
- Market perception remains cautious due to broader economic conditions impacting consumer spending on healthcare products.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $2.70B | $57M | $0.04 |
| Q2 2025 | $3.74B | $339M | $0.26 |
| Q4 2024 | $3.21B | $93M | $0.07 |
| Q2 2024 | $4.05B | $429M | $0.33 |
Based on FMP financials and quantitative analysis
TGRNF Latest News
No recent news available for TGRNF.
TGRNF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for TGRNF.
Price Targets
Wall Street price target analysis for TGRNF.
TGRNF MoonshotScore
What does this score mean?
The MoonshotScore rates TGRNF 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Yi Zhang
CEO
Yi Zhang has been at the helm of Tong Ren Tang Technologies Co. Ltd. for several years, bringing extensive experience in the healthcare and pharmaceutical industries. With a strong educational background in business management and healthcare, he has played a pivotal role in driving the company's strategic vision and operational effectiveness. Prior to his current role, Yi held various leadership positions within the organization, contributing to its growth and innovation in traditional Chinese medicine.
Track Record: Under Yi Zhang's leadership, Tong Ren Tang has successfully expanded its product offerings and improved operational efficiencies. He has spearheaded initiatives to enhance the company's research and development capabilities, positioning it for future growth in the competitive healthcare market.
TGRNF OTC Market Information
The OTC Other tier indicates that Tong Ren Tang Technologies Co. Ltd. trades on the over-the-counter market, which typically has less stringent reporting requirements compared to major exchanges like NYSE or NASDAQ. This tier may include companies with lower trading volumes and less visibility, potentially impacting investor confidence.
- OTC Tier: OTC Other
- Limited financial transparency due to lower disclosure requirements.
- Potential for higher volatility compared to stocks on major exchanges.
- Liquidity challenges may arise, impacting the ability to buy or sell shares.
- Regulatory risks associated with OTC trading.
- Review the company's financial health and operational metrics.
- Investigate the regulatory environment for TCM products.
- Evaluate the competitive landscape and market positioning.
- Assess the company's growth strategies and potential risks.
- Monitor news and updates related to the healthcare sector.
- Established brand with over 350 years of history.
- Diverse product portfolio and strong market presence.
- Commitment to quality and traditional practices in TCM.
- Engagement in research and development for product innovation.
Tong Ren Tang Technologies Co. Ltd. Healthcare Stock: Key Questions Answered
What does the AI Score mean for TGRNF?
TGRNF holds an AI Score of 48/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. Tong Ren Tang Technologies Co. Ltd. specializes in the manufacturing and marketing of traditional Chinese medicine products, with a history dating back to 1669. The company operates primarily …
What does Tong Ren Tang Technologies Co. Ltd. do?
Tong Ren Tang Technologies Co. Ltd. specializes in the manufacturing and marketing of traditional Chinese medicine products. The company also cultivates and procures Chinese medicinal raw materials, produces a diverse range of healthcare and wellness items, and offers medical research and development services. Its extensive product portfolio includes pharmaceuticals, cosmetics, and specialized healthcare solutions, primarily serving the Mainland China and Hong Kong markets.
What are the main risks for TGRNF?
Tong Ren Tang Technologies Co. Ltd. faces several risks, including potential regulatory challenges that could impact its operations in the traditional medicine sector. Additionally, the company encounters ongoing competition from both local and international players, which may affect market share. Market fluctuations can also impact raw material costs, posing a threat to profitability. Finally, changing consumer preferences towards alternative health solutions could influence demand for TCM products.
How does Tong Ren Tang Technologies Co. Ltd. navigate regulatory approval processes?
Tong Ren Tang Technologies Co. Ltd. adheres to stringent regulatory standards in the healthcare sector, particularly concerning the production and marketing of traditional Chinese medicine products. The company actively engages with regulatory bodies to ensure compliance with local and international guidelines. This includes obtaining necessary certifications and approvals for its product lines and maintaining quality control measures.
What are the key factors to evaluate for TGRNF?
Tong Ren Tang Technologies Co. Ltd. (TGRNF) holds an AI score of 48/100 (low). P/E: 10.1x vs the S&P 500's ~20-25x. Not financial advice.
How frequently does TGRNF data refresh on this page?
TGRNF's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven TGRNF's recent stock price performance?
Tong Ren Tang Technologies Co. Ltd. (TGRNF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Rich heritage and established brand recognition in TCM. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider TGRNF overvalued or undervalued right now?
Tong Ren Tang Technologies Co. Ltd. (TGRNF) trades at 10.1x earnings. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research TGRNF before investing?
Before investing in Tong Ren Tang Technologies Co. Ltd. (TGRNF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data is based on the latest available information and may be subject to change.